Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Purple Innovation Q1 2026 Earnings Call - Accounting Adjustments and Premium Product Pivot
Purple Innovation's first quarter was a study in structural transition. While top-line revenue fell 8% year-over-year, much of the headline volatility stems from a $4.9 million accounting reclassifica...
- Total net revenue declined 8.1% year-over-year, though this includes a $4.9 million accounting-related reduction in wholesale revenue.
- Excluding the accounting impact, net revenue would have been $100.6 million, representing only a 3.4% decline.
- Showroom performance remains the primary bright spot, with sales up 5% and comparable sales increasing by 7%.
- +8 more takeaways
Omnicell Q1 2026 Earnings Call - Transition to Titan XT and OmniSphere Drives Margin Expansion
Omnicell opened 2026 with a performance that suggests the company is successfully navigating a critical technological pivot. By beating top-end guidance across key metrics, management signaled that th...
- Total revenue for Q1 2026 reached $310 million, marking a 15% year-over-year increase.
- Non-GAAP EBITDA rose significantly to $45 million from $24 million in the prior year period.
- Non-GAAP EPS was $0.55, a substantial improvement over the $0.26 reported in Q1 2025.
- +8 more takeaways
Novartis Q1 2026 Earnings Call - Priority Brands Drive Growth Amidst Generic Erosion
Novartis opened 2026 with a tale of two halves. On one side, the company's priority brands and new launches are firing on all cylinders, posting a combined 34% growth in constant currency. Kisqali, Pl...
- Priority brands and new launches delivered 34% growth in constant currency during Q1.
- Kisqali saw 55% growth, bolstered by strong market share in early breast cancer (65%+ NBRX in the U.S.).
- Pluvicto sales grew 76% in the U.S., driven largely by the pre-taxane mCRPC setting.
- +9 more takeaways
Kiniksa Q1 2026 Earnings Call - ARCALYST Revenue Surges as Pipeline Milestones Loom
Kiniksa delivered a powerhouse first quarter, driven by the relentless commercial momentum of ARCALYST. Net revenue for the franchise hit $214.3 million, a 56% year-over-year jump that effectively shr...
- ARCALYST net revenue reached $214.3 million in Q1 2026, a 56% increase year-over-year.
- Kiniksa raised its full-year 2026 revenue guidance to $930 million–$945 million from the previous $900 million–$920 million range.
- New prescriber growth hit a post-launch high, with approximately 400 new prescribers added in Q1 alone.
- +8 more takeaways
Brown & Brown Q1 2025 Earnings Call - Specialty Distribution and AI Integration Drive Resilient Margins Amid Property Rate Volatility
Brown & Brown delivered a robust first quarter, characterized by massive top-line growth of 35.4% fueled largely by the Accession acquisition. While organic revenue growth remained relatively flat due...
- Total revenues surged 35.4% year-over-year to $1.9 billion, largely driven by the integration of Accession.
- Adjusted EBITDAC margins expanded by 40 basis points to 38.5%, showcasing strong expense discipline and margin protection.
- Contingent commissions grew by an impressive $54 million, providing a critical buffer against organic growth pressures.
- +7 more takeaways
Hillman Solutions Q1 2026 Earnings Call - Navigating Tariff Headwinds and Pro Channel Expansion
Hillman Solutions delivered a mixed first quarter, characterized by a 3% increase in net sales but an 8% drop in Adjusted EBITDA. The company faced a perfect storm of seasonal softness in January and ...
- Net sales for Q1 2026 grew 3% year-over-year to $370.1 million, despite a slow start in January and February.
- Adjusted EBITDA fell 8% to $50.1 million, pressured by high-cost tariff inventory and soft volume in specific segments.
- Management raised full-year net sales guidance to a midpoint of $1.68 billion, an 8% increase over last year.
- +8 more takeaways
Spotify Q1 2026 Earnings Call - Scaling the AI-Driven Personalization Era
Spotify entered its second decade with a clear, aggressive pivot from a passive music streamer to an interactive, AI-driven media platform. The first quarter of 2026 showed a company successfully navi...
- Spotify surpassed 760 million Monthly Active Users (MAUs), exceeding guidance by 2 million.
- The company achieved its second-highest gross margin ever at 33%, driven by revenue mix and cost efficiencies.
- Subscribers grew by 3 million net additions, reaching a total of 293 million.
- +7 more takeaways
Rithm Capital Q1 2026 Earnings Call - Exploiting Market Dislocations and Asset Management Growth
Rithm Capital delivered a robust first quarter, characterized by strong performance across its diverse operating segments. CEO Michael Nierenberg framed the current macro environment as a gift, noting...
- Rithm Capital reported $289.6 million in earnings for Q1 2026, representing a 17% return on equity.
- CEO Michael Nierenberg views current private credit market volatility as a sentiment-driven dislocation rather than systemic risk, providing opportunities to deploy capital.
- The company rebranded its real estate arm, Paramount Group, to Elecor Properties, focusing on Class A office assets in New York and San Francisco.
- +8 more takeaways
Sportradar Q1 2026 Earnings Call - Fighting Short Sellers with Massive Buybacks and Prediction Market Bets
Sportradar's first quarter was a study in resilience against headwinds. Despite facing aggressive short-seller allegations regarding regulatory compliance and navigating unfavorable foreign exchange m...
- Sportradar reported Q1 2026 revenues of EUR 347 million, an 11% increase year-over-year.
- The company announced a new $250 million enhanced open market repurchase program under its existing $1 billion authorization.
- CEO Carsten Koerl aggressively dismissed recent short-seller reports as unfounded and aimed at driving down the stock price.
- +9 more takeaways
Incyte Q1 2026 Earnings Call - Transitioning Beyond Jakafi via Pipeline Diversification
Incyte delivered a robust start to 2026, reporting a 21% jump in total revenue to $1.27 billion. The company is aggressively executing a strategic pivot designed to reduce its reliance on the cornerst...
- Total revenue for Q1 2026 rose 21% year-over-year to $1.27 billion, with net sales up 20%.
- Incyte is executing a strategic shift to move beyond Jakafi, targeting a core business (ex-Jakafi) of $3 billion to $4 billion by 2030.
- The FDA accepted the regulatory application for povorcitinib in patients with moderate to severe Hidradenitis Suppurativa (HS).
- +9 more takeaways